Novavax (NVAX)
(Delayed Data from NSDQ)
$14.40 USD
-0.65 (-4.32%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $14.30 -0.10 (-0.69%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Novavax, Inc. [NVAX]
Reports for Purchase
Showing records 261 - 280 ( 299 total )
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Phase I/II vaccine that uses Novavax''s Isconova adjuvant the subject of a Late Breaker at the upcoming ICAAC conference, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q2:13 EPS, Broad Vaccine Platform Continues to Progress, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Research coverage are Under Review pending reassignment to a new analyst.
Provider: BRINSON PATRICK SECURITIES CORPORATION
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
H7N9 Vaccine Construct Enters Clinic, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Positive Elderly RSV Data Paves Way for RSV/FLU Upper Respiratory Combination Product
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
NVAX Secures Proprietary Vaccine Adjuvant Platform -- MERS-CoV Vaccine Development Update - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Some Key Questions with RSV Answered in 1Q13
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
News of a Lethal New Influenza Reported from China Relevant
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
RSV Vaccine Phase II Results in Women of Childbearing Age Positive , Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q4:12 Update-Top-Line RSV Results Now April, Flu Data
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating research coverage due to the termination or loss of the primary and/or secondary analysts responsible for coverage.
Provider: DAWSON JAMES SECURITIES, INC.
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q3:12 Update - Top-Line RSV Results Q1:13 - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Strong Momentum Going into 2013
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Strong Momentum Going into 2013
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Initiation: Doors opening for this vaccine innovator
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Pandemic Flu Vaccine Data Exceptionally Positive, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G